Bio-Technology General Corp. said Tuesday that it has finalizedan exclusive agreement with Tedec Zambeletti of Madrid,Spain, to distribute BTGC's hyaluronic acid-based ophthalmicsurgical aids in Spain and Portugal. Zambeletti will makeguaranteed minimum purchases of HA-filled syringes fromBTGC.

Stock of the New York-based company (NASDAQ:BTGC) closed at$5.50, down 25 cents, on Tuesday.

BTGC said it expects its European marketing partners --including Zambeletti, Laboratoire Chauvin for France and theBenelux countries, and Nimrod AB for Scandinavia -- to beginfiling this year for marketing approvals of HA in theirrespective regions. The companies will use data from clinicaltrials that BTGC conducted in Israel.

(c) 1997 American Health Consultants. All rights reserved.